Toll Free: 1-888-928-9744

Becker Muscular Dystrophy - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Becker Muscular Dystrophy - Pipeline Review, H1 2016


Global Markets Direct's, 'Becker Muscular Dystrophy - Pipeline Review, H1 2016', provides an overview of the Becker Muscular Dystrophy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy
- The report reviews pipeline therapeutics for Becker Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Becker Muscular Dystrophy therapeutics and enlists all their major and minor projects
- The report assesses Becker Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Becker Muscular Dystrophy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Becker Muscular Dystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Becker Muscular Dystrophy Overview 6 Therapeutics Development 7 Pipeline Products for Becker Muscular Dystrophy - Overview 7 Becker Muscular Dystrophy - Therapeutics under Development by Companies 8 Becker Muscular Dystrophy - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Becker Muscular Dystrophy - Products under Development by Companies 12 Becker Muscular Dystrophy - Companies Involved in Therapeutics Development 13 Milo Biotechnology LLC 13 PTC Therapeutics, Inc. 14 ReveraGen BioPharma, Inc. 15 Sarepta Therapeutics, Inc. 16 Sphaera Pharma Pvt. Ltd. 17 Becker Muscular Dystrophy - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 AAV1-Foliistatin - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ARM-210 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ataluren - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 epicatechin - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule for Becker Muscular Dystrophy - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 vamorolone - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Becker Muscular Dystrophy - Recent Pipeline Updates 38 Becker Muscular Dystrophy - Dormant Projects 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for Becker Muscular Dystrophy, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2016 13 Becker Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H1 2016 14 Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H1 2016 15 Becker Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H1 2016 16 Becker Muscular Dystrophy - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Becker Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H1 2016 38 Becker Muscular Dystrophy - Dormant Projects, H1 2016 46

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.